Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jalpa Doshi"'
Autor:
Mahek Garg, Justin Puckett, Sachin Kamal-Bahl, Monika Raut, Katherine Ryland, Samhita Chakraborty, Jalpa Doshi, Scott Huntington
Publikováno v:
HemaSphere, Vol 7, p e7912542 (2023)
Externí odkaz:
https://doaj.org/article/2f6db66848ce4de19526b2feba3dc69c
Autor:
Enrico De Nigris, Scott F. Huntington, Justin Puckett, Sachin Kamal-Bahl, Mohammed Z.H. Farooqui, Katherine Elizabeth Ryland, Eric Sarpong, Xiaoqin Yang, Jalpa Doshi
Publikováno v:
Blood. 140:5043-5044
Autor:
Patrick Squires, Scott F. Huntington, Justin Puckett, Katherine Elizabeth Ryland, Sachin Kamal-Bahl, Monika Raut, Jalpa Doshi
Publikováno v:
Blood. 140:5041-5042
Autor:
Scott F. Huntington, Enrico De Nigris, Justin Puckett, Sachin Kamal-Bahl, Mohammed Z.H. Farooqui, Katherine Elizabeth Ryland, Eric Sarpong, Xiaoqin Yang, Jalpa Doshi
Publikováno v:
Blood. 140:7939-7940
Autor:
Mahek Garg, Scott F. Huntington, Justin Puckett, Sachin Kamal-Bahl, Monika Raut, Katherine Elizabeth Ryland, Jalpa Doshi
Publikováno v:
Blood. 140:10814-10815
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 4
OBJECTIVES: The impact of Medicare's Part D coverage gap (donut hole) on antihypertensive and antilipidemic drug utilization was examined among patients with diabetes or coronary heart disease (CHD) and compared to changes in drug use for symptomatic
Publikováno v:
LDI issue brief. 13(3)
Rising obesity represents one of the most disturbing health trends in the U.S. and elsewhere. Obese people are at greater risk for diabetes, cardiovascular disease, disability, and mortality. However, recent studies also suggest that the obese popula
Publikováno v:
Health affairs (Project Hope).
Employer-sponsored health insurance is often described as the most reliable private source of Medicare supplementation, particularly for prescription drug benefits. This study's findings show that employer coverage is becoming an increasingly less de
Publikováno v:
Health Care Financing Review
MCBS data are used to analyze the predictability of drug expenditures by Medicare beneficiaries. Predictors include demographic characteristics and measures of health status, the majority derived using CMS' diagnosis cost group/hierarchical condition
Publikováno v:
Chest. 144:695A